Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.65 AUD | +1.56% | -1.52% | +21.50% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.50% | 8.62Cr | - | ||
+29.80% | 68TCr | C+ | ||
+29.45% | 57TCr | B | ||
-4.04% | 36TCr | C+ | ||
+18.71% | 33TCr | B- | ||
+4.56% | 28TCr | C+ | ||
+15.89% | 24TCr | B+ | ||
+9.33% | 21TCr | B- | ||
-7.03% | 20TCr | A+ | ||
+7.66% | 17TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RCE Stock
- Ratings Recce Pharmaceuticals Ltd